| Code | CSB-RA019093MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is developed as a research-grade biosimilar to NTX-1088, targeting PVR (poliovirus receptor, also known as CD155 or nectin-like molecule 5). PVR is a type I transmembrane glycoprotein that plays crucial roles in cell adhesion, migration, and immune regulation. It functions as a key immune checkpoint molecule by interacting with both stimulatory receptor CD226 (DNAM-1) and inhibitory receptors TIGIT and CD96 on immune cells. PVR is frequently overexpressed in various malignancies, including colorectal, pancreatic, lung, and ovarian cancers, where it contributes to tumor immune evasion by suppressing natural killer cell and T cell responses.
NTX-1088 represents an investigational therapeutic antibody designed to block PVR-mediated immunosuppressive signaling, thereby enhancing anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating PVR biology, tumor-immune interactions, and immune checkpoint mechanisms in oncology. It supports preclinical studies examining PVR's role in cancer progression, metastasis, and resistance to immunotherapy, as well as exploration of combination therapeutic strategies targeting multiple immune checkpoints.
There are currently no reviews for this product.